OBJECTIVE: To evaluate the risk for developing metabolic syndrome when having depressive symptoms. METHOD: The prevalence of depressive symptoms and metabolic syndrome at baseline, and after a 7-year follow-up as measured with Beck depression inventory (BDI), and using the modified National Cholesterol Education Program--Adult Treatment Panel III criteria for metabolic syndrome (MetS) were studied in a middle-aged population-based sample (n = 1294). RESULTS: The logistic regression analysis showed a 2.5-fold risk (95% CI: 1.2-5.2) for the females with depressive symptoms (BDI >or=10) at baseline to have MetS at the end of the follow-up. The risk was highest in the subgroup with more melancholic symptoms evaluated with a summary score of the melancholic items in BDI (OR 6.81, 95% CI: 2.09-22.20). In men, there was no risk difference. CONCLUSION: The higher risks for MetS in females with depressive symptoms at baseline suggest that depression may be an important predisposing factor for the development of MetS.
OBJECTIVE: To evaluate the risk for developing metabolic syndrome when having depressive symptoms. METHOD: The prevalence of depressive symptoms and metabolic syndrome at baseline, and after a 7-year follow-up as measured with Beck depression inventory (BDI), and using the modified National Cholesterol Education Program--Adult Treatment Panel III criteria for metabolic syndrome (MetS) were studied in a middle-aged population-based sample (n = 1294). RESULTS: The logistic regression analysis showed a 2.5-fold risk (95% CI: 1.2-5.2) for the females with depressive symptoms (BDI >or=10) at baseline to have MetS at the end of the follow-up. The risk was highest in the subgroup with more melancholic symptoms evaluated with a summary score of the melancholic items in BDI (OR 6.81, 95% CI: 2.09-22.20). In men, there was no risk difference. CONCLUSION: The higher risks for MetS in females with depressive symptoms at baseline suggest that depression may be an important predisposing factor for the development of MetS.
Authors: Marko Wahlman; Arja Häkkinen; Joost Dekker; Ilkka Marttinen; Kimmo Vihtonen; Marko H Neva Journal: Eur Spine J Date: 2013-07-24 Impact factor: 3.134
Authors: Debra L Foley; Katherine I Morley; Pamela A F Madden; Andrew C Heath; John B Whitfield; Nicholas G Martin Journal: Twin Res Hum Genet Date: 2010-08 Impact factor: 1.587
Authors: Nicole Vogelzangs; Aartjan T F Beekman; Ingrid G Boelhouwer; Stefania Bandinelli; Yuri Milaneschi; Luigi Ferrucci; Brenda W J H Penninx Journal: J Clin Psychiatry Date: 2011-04-05 Impact factor: 4.384
Authors: Jussi Seppälä; Hannu Koponen; Hannu Kautiainen; Johan G Eriksson; Olli Kampman; Jaana Leiviskä; Satu Männistö; Pekka Mäntyselkä; Heikki Oksa; Yrjö Ovaskainen; Merja Viikki; Mauno Vanhala; Jussi Seppälä Journal: BMC Psychiatry Date: 2013-05-24 Impact factor: 3.630